Shandong pharmaceutical company will win over 4 billion rosuvastatin calcium tablets

Recently, the listing application of Shandong Lukang Pharmaceutical's 4 generic drug rosuvastatin calcium tablets has entered the administrative approval stage
.
According to data from Mi Nei.
com, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China will exceed 4 billion yuan in 2020
.
Source: The official website of the State Food and Drug Administration.
Rosuvastatin is a selective and competitive HMG-CoA reductase inhibitor.
It is clinically mainly used for diet control and other non-drug treatments (such as exercise therapy, weight loss).
Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) that cannot properly control dyslipidemia
.
At present, more than 20 domestic companies have production approvals for rosuvastatin calcium tablets.
According to data from Meinenet, this product will be used in urban public hospitals, county-level public hospitals, urban community centers, and township health centers in China in 2020 (referred to as Chinese public medical institutions).
) And the total sales of physical pharmacies in Chinese cities exceeded 4 billion yuan, of which the sales growth of public medical institutions in China declined by more than 50% (affected by centralized procurement), while the sales of physical pharmacies in Chinese cities still had 9.
7% Sales growth rate
.
Sales of terminal blood lipid regulators in physical pharmacies in Chinese cities (unit: 10,000 yuan) Source: Menet.
com.
China’s city physical pharmacies terminal competition pattern.
According to data from Meine.
com, the market for terminal blood lipid regulators in physical pharmacies in cities in China has continued to expand in recent years.
It is expected to be in 2021.
Breaking through 5 billion yuan, an increase of 3.
32% year-on-year
.
2021E China's urban physical pharmacy terminal blood lipid regulator TOP5 product source: Mynet.
com China's urban physical pharmacy terminal competition pattern China's urban physical pharmacy terminal blood lipid regulator market is highly concentrated, and the total market share of TOP5 products is expected to exceed 80% in 2021
.
Atorvastatin calcium tablets and rosuvastatin calcium tablets have been ranked first and second for many years.
Innovative drugs iloyuumab (Amgen) and alisiyuumab (Sanofi) have increased significantly and their sales have increased.
Speed ​​will exceed 100%
.
From the perspective of the competitive landscape of manufacturers, the end-lipid regulator market in China's urban physical pharmacies is dominated by multinational companies.
Pfizer and AstraZeneca have been ranked first and second for many years
.
With the rapid increase in volume of innovative drugs, Amgen is expected to be among the TOP3 manufacturers for the first time in 2021
.
Note: Meinenet database, the official website of the State Food and Drug Administration, etc.
Note: Meinenet China's urban entity pharmacy terminal competition pattern database covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), continuous for all categories Monitored enlarged version of the city's physical pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of December 15th, if there are any omissions, please correct me!